FivepHusion is a private Australian biotechnology company headquartered in New South Wales, founded in 2018.
FivepHusion is developing Deflexifol™, a novel drug formulation created to address oncologists’ needs for safer and more efficacious chemotherapy. Deflexifol™ research and development was originally conducted at the University of Wollongong (UoW), with IP assigned to FivepHusion. The company maintains an ongoing ...
FivepHusion is a private Australian biotechnology company headquartered in New South Wales, founded in 2018.
FivepHusion is developing Deflexifol™, a novel drug formulation created to address oncologists’ needs for safer and more efficacious chemotherapy. Deflexifol™ research and development was originally conducted at the University of Wollongong (UoW), with IP assigned to FivepHusion. The company maintains an ongoing collaboration with UoW. FivepHusion’s vision is to optimise standard of care cancer therapy to improve patient outcomes and quality of life, leading to a better future for patients.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.